- Home
- LINC vs ATXS Comparison
LINC vs ATXS Comparison
Compare LINC & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LINC
- ATXS
- Stock Information
- Founded
- LINC 1946
- ATXS 2008
- Country
- LINC United States
- ATXS United States
- Employees
- LINC N/A
- ATXS N/A
- Industry
- LINC Other Consumer Services
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- LINC Real Estate
- ATXS Health Care
- Exchange
- LINC Nasdaq
- ATXS Nasdaq
- Market Cap
- LINC 499.3M
- ATXS 516.4M
- IPO Year
- LINC 2005
- ATXS 2015
- Fundamental
- Price
- LINC $16.20
- ATXS $7.57
- Analyst Decision
- LINC Strong Buy
- ATXS Strong Buy
- Analyst Count
- LINC 4
- ATXS 5
- Target Price
- LINC $18.00
- ATXS $25.60
- AVG Volume (30 Days)
- LINC 170.1K
- ATXS 340.8K
- Earning Date
- LINC 02-24-2025
- ATXS 03-03-2025
- Dividend Yield
- LINC N/A
- ATXS N/A
- EPS Growth
- LINC N/A
- ATXS N/A
- EPS
- LINC 0.32
- ATXS N/A
- Revenue
- LINC $423,213,000.00
- ATXS N/A
- Revenue This Year
- LINC $16.43
- ATXS N/A
- Revenue Next Year
- LINC $8.66
- ATXS N/A
- P/E Ratio
- LINC $50.43
- ATXS N/A
- Revenue Growth
- LINC 15.21
- ATXS N/A
- 52 Week Low
- LINC $8.91
- ATXS $7.16
- 52 Week High
- LINC $18.74
- ATXS $16.90
- Technical
- Relative Strength Index (RSI)
- LINC 59.69
- ATXS 31.15
- Support Level
- LINC $14.31
- ATXS $7.45
- Resistance Level
- LINC $15.54
- ATXS $7.95
- Average True Range (ATR)
- LINC 0.52
- ATXS 0.40
- MACD
- LINC 0.09
- ATXS -0.06
- Stochastic Oscillator
- LINC 98.44
- ATXS 20.30
About LINC Lincoln Educational Services Corporation
Lincoln Educational Services Corp provides diversified career-oriented post-secondary education to high school graduates and working adults. The company offers programs in automotive technology, skilled trades, healthcare services, hospitality services and business and information technology. Its reportable segments include; Campus Operations, and Transitional. Majority of the revenue is generated from Campus Operations segment which includes all campuses that are continuing in operation and contribute to the Company's core operations and performance.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.